Company Overview of Tocagen Inc.
Tocagen Inc. is a clinical-stage biopharmaceutical company that engages in the discovery, development, and commercialization of gene therapy products for the selective treatment of cancer. The company focuses on developing a treatment for high grade glioma, a type of brain cancer that includes glioblastoma multiforme and anaplastic astrocytomas. Its products include Toca 511 and Toca FC that allows selective targeting of cancer cells, as well as a selective, local, and systemic antitumor immune response without off-target toxicity; Toca Gamma that leverages the immune system to clear locally injected cancerous tumors, as well as to create an arsenal of targeted immune cells to kill more dist...
3030 Bunker Hill Street
San Diego, CA 92109
Founded in 2007
Key Executives for Tocagen Inc.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Executive Vice President of Research & Pharmaceutical Development
Co-Founder, Executive Vice President of Corporate Development and Director
Chief Financial Officer, Executive Vice President and Director
Head of Business Development and Product Manager
Compensation as of Fiscal Year 2014.
Tocagen Inc. Key Developments
Tocagen Inc. Appoints David R. Parkinson, M.D., to the Board of Directors
May 5 15
Tocagen Inc. announced that David R. Parkinson, M.D., a venture partner at New Enterprise Associates (NEA), has been appointed to the board of directors of Tocagen. Among other prior roles, Dr. Parkinson was vice president of oncology development at Amgen, vice president of global clinical oncology development at Novartis and senior vice president at Biogen Idec, leading oncology research and development. Dr. Parkinson presently serves on the board of directors of Threshold Pharmaceuticals and Cerulean Pharma Inc. and previously served on the board of directors of Facet Biotech, acquired by Abbott, and Ambit Biosciences Corporation, acquired by Daiichi Sankyo.
Tocagen to Present Updated Interim Results from Studies Evaluating Toca 511 & Toca FC at the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Tumors
Apr 30 15
Tocagen Inc. announced updated interim results from ongoing investigational studies of Toca 511 in combination with Toca FC will be presented by two principal investigators at the 11th Biennial Satellite Symposium of the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors, to be held May 1-2, 2015, in Washington, D.C. Toca 511 & Toca FC is being investigated in four clinical trials in patients with recurrent high grade glioma, including glioblastoma. A pivotal Phase 2/3 study in patients with recurrent glioblastoma or anaplastic astrocytoma (the "Toca 5" study) is anticipated to initiate in 2015. The combination of Toca 511 & Toca FC is designed to break immune tolerance to the tumor using a combination of mechanisms. Toca 511, a retroviral replicating vector (RRV), delivers a prodrug-activating gene selectively to cancer cells. Then the prodrug-activating enzyme produced in the cancer cell is designed to activate orally administered Toca FC, an investigational extended-release formulation of 5-fluorocytosine (5-FC), into a powerful antimetabolite, 5FU, which kills the infected cancer cell and neighboring 5-FU sensitive tumor cells. Glioma cells and myeloid derived suppressor cells in the tumor are known to be sensitive to 5-FU. In animal models, the production of 5-FU locally kills dividing tumor cells during each 5-FC cycle, which leads to durable and selective anticancer immune responses. Data from ongoing clinical trials show encouraging evidence for increased survival compared to historical benchmarks, excellent safety, and evidence to support the proposed mechanism of action.
Tocagen Appoints Paul Schimmel to the Board of Directors
Feb 25 15
Tocagen Inc. announced that Paul Schimmel, Ph.D., Hahn professor of molecular biology and chemistry at The Scripps Research Institute, has been appointed to the board of directors. Dr. Schimmel co-founded Alnylam Pharmaceuticals and currently serves as a member of the company's board of directors.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|